Skip to main content

Table 2 Likelihood for starting continuous treatment with medication for attention-deficit/hyperactivity disorder (ADHD) comparing individuals with and without autism spectrum disorder (ASD)

From: Medications for attention-deficit/hyperactivity disorder in individuals with or without coexisting autism spectrum disorder: analysis of data from the Swedish prescribed drug register

  ADHD without coexisting ASD ADHD with coexisting ASD Model 1# Model 2##
  Frequency (%) Frequency (%) Odds ratio (95% confidence interval) Odds ratio (95% confidence interval)
All individuals n = 34,374 n = 5012   
 No treatment 6706 (19.5) 1191 (23.8)   
 Continuous treatment 27,668 (80.5) 3821 (76.2) 0.77 (0.72-0.83)### 0.80 (0.75-0.86)###
Adults n = 17447 n = 2243   
 No treatment 4062 (23.3) 621 (27.7)   
 Continuous treatment 13,385 (76.7) 1622 (72.3) 0.82 (0.74-0.91)### 0.85 (0.77-0.94)###
Adolescents n = 7784 n = 1070   
 No treatment 1319 (17.95) 237 (22.15)   
 Continuous treatment 6465 (83.05) 833 (77.85) 0.74 (0.63-0.86)### 0.76 (0.65-0.89)###
Children n = 9143 n = 1699   
 No treatment 1325 (14.5) 333 (19.6)   
 Continuous treatment 7818 (85.5) 1366 (80.4) 0.72 (0.63-0.82)### 0.76 (0.66-0.87)###
  1. Note: An odds ratio below one indicate that individuals with ADHD and ASD are less likely to receive medication. Included medications in the analysis: methylphenidate, atomoxetine, dexamphetamine, modafinil, and amphetamine. “No treatment”, individuals with zero or one single filled prescription. “Continuous treatment”. two or more filled prescriptions. Age categories based on age at first ADHD diagnosis (adults, age ≥ 18 years; adolescents, age 13-17 years; children, age ≤ 12 years)
  2. #Adjusted for sex and birth categories in years, and year of first ADHD diagnosis
  3. ##Adjusted for sex, birth categories in years, year of first ADHD diagnosis, and psychiatric comorbidities before first dispense date
  4. ###p value < 0.0001